Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432708 | 0.94 | PIK3C3 (0.33) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29605672 | 0.94 | PIK3C3 (0.33) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL19275744 | 0.90 | PIK3C3 (0.36) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL17545524 | 0.84 | ALDH1A1 (0.39) | PIK3C3CNR2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL20626868 | 0.82 | CNR2 (0.30) | CNR2L3MBTL1 | |
| SCHEMBL14968843 | 0.81 | PIK3C3 (0.35) | PIK3C3 | |
| SCHEMBL18948262 | 0.80 | CA12 (0.33) | ALDH1A1 | |
| SCHEMBL16219932 | 0.80 | L3MBTL3 (0.37) | PIK3C3CNR2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL19574059 | 0.80 | CHRNB4 (0.36) | CNR2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL24955562 | 0.79 | CHRM2 (0.33) | PIK3C3CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | claimed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | claimed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | CCR2, CCRL2, CCR1 | PIK3C3 4806/4885CNR2 30/4885CHRNB4 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.